Union européenne - espagnol - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - infecciones neumocócicas - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. ver secciones 4. 4 y 5. 1 para obtener información sobre la protección contra serotipos neumocócicos específicos. the use of vaxneuvance should be in accordance with official recommendations.

Espagne - espagnol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

reckitt benckiser healthcare s.a. - flurbiprofeno - soluciÓn para pulverizaciÓn bucal - 8,75 mg/dosis (3 pulsaciones) - flurbiprofeno 8,75 mg - flurbiprofeno

Espagne - espagnol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kalceks as - dexmedetomidina hidrocloruro - concentrado para soluciÓn para perfusiÓn - 100 microgramos/ml inyectable 10 ml - dexmedetomidina hidrocloruro 100 microgramos - dexmedetomidina

Union européenne - espagnol - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - agentes antineoplásicos - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Union européenne - espagnol - EMA (European Medicines Agency)

merck sharp & dohme b.v. - gefapixant - cough - preparaciones para la tos y el resfriado - lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.